Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson, BioGX Get FDA Emergency Use Authorization for Rapid SARS-CoV-2 Test

NEW YORK – Becton Dickinson and BioGX announced Friday that they received Emergency Use Authorization from the US Food and Drug Administration for a hospital SARS-CoV-2 test.

The rapid test is for hospital use on site to screen patients and healthcare workers and offers results in less than three hours from nasopharyngeal and oropharyngeal swabs. BioGX's test will run on the BD Max system, which processes 24 samples at once. 

BioGX developed the Sample-Ready ready-to-use assay for the BD Max system, and it is based on the same viral RNA targeting sequences and PCR detection as the assay from the US Centers for Disease Control and Prevention, which received EUA in February.

The fully automated BD Max platform, which can process 24 samples simultaneously, is installed in "hundreds" of laboratories in almost every state in the US, the two companies said, and the new test will add capacity for 50,000 tests per week across the country.

BD and BioGX submitted the test to FDA in mid-March for EUA.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.